Oxime-Based Compounds for Neutrophil Elastase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds used to inhibit neutrophil elastase and proteinase 3, such as sivelestat, have complex and hazardous manufacturing processes and limited pharmacokinetic effects, and their ability to treat inflammation disorders is not fully proven, particularly in vivo.
Innovation Solution
Development of oxime-based compounds with specific formulas that inhibit neutrophil elastase and proteinase 3, including a method for their preparation, which are safer to manufacture and more effective in treating inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sivelestat is used to inhibit neutrophil elastase, then the inhibitory effect is achieved, but the manufacturing process becomes complex and hazardous
Solution Approach 1:
The patent modifies the chemical structure of sivelestat by changing parameters such as the ester group (pivaloyloxy vs. other esters), amino acid residues (glycine vs. other amino acids), and aromatic substituents to develop compounds with improved manufacturability while maintaining neutrophil elastase inhibitory activity. This allows safer synthesis routes with fewer hazardous steps.
2Reliability
If sivelestat is used to inhibit neutrophil elastase, then the inhibitory effect is achieved, but the pharmacokinetic effect is limited
Solution Approach 1:
The patent systematically varies pharmacokinetic parameters by modifying molecular weight (through different amino acid choices), lipophilicity (through aromatic substituent variations), and metabolic stability (through ester group selection) to achieve compounds with prolonged duration of action and improved pharmacokinetic profiles compared to sivelestat.
3Reliability
If existing compounds are used to treat inflammation disorders, then some therapeutic effect is achieved, but the efficacy in vivo is not fully proven
Solution Approach 1:
The patent employs comprehensive in vivo evaluation models including acute lung injury models, edema models, and other inflammation disorder models to systematically assess and verify the therapeutic effects of the compounds. This feedback loop allows optimization of compound structures based on actual in vivo performance data, providing robust evidence for efficacy.
Data Source
AI summary
An oxime-based compound having the following formula (I) or a pharmaceutically acceptable salt thereof:wherein:Y is a carbonyl group or a sulfonyl group;R1 is selected from H, OH, a C1-C4 alkyl group, and a C1-C4 alkoxyl group;R2 is selected from OH, a methoxyl group, —OR4OH, and —OR4NH2, R4 being a C1-C3 alkyl group; andR3 is H or a pivaloyloxybenzenesulfonyl group.